Helix BioPharma Corp (HBP) - Financial and Strategic SWOT Analysis Review

Helix BioPharma Corp (HBP) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

    • Business description – A detailed description of the company’s operations and business divisions.
    • Corporate strategy – Analyst’s summarization of the company’s business strategy.
    • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
    • Company history – Progression of key events associated with the company.
    • Major products and services – A list of major products, services and brands of the company.
    • Key competitors – A list of key competitors to the company.
    • Key employees – A list of the key executives of the company.
    • Executive biographies – A brief summary of the executives’ employment history.
    • Key operational heads – A list of personnel heading key departments/functions.
    • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
    • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
    • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
    Highlights

    Helix BioPharma Corp (Helix) is a biopharmaceutical company with a focus in the field of cancer therapy. It develops drug candidates for the prevention and treatment of cancer. The company develops drugs based on DOS47, its proprietary broad anti-cancer therapeutic platform. DOS47 has yielded two new drug product candidates, V-DOS47 and L-DOS47. V-DOS47 uses the company’s proprietary DOS47 technology conjugated to VEGFR target wide range of cancers and L-DOS47 is designed to treat inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). It also continues to actively pursue additional novel antibody based technologies for cell-based therapies. Helix is headquartered in Ontario, Canada.

    Helix BioPharma Corp Key Recent Developments

    Oct 24,2019: Helix BioPharma announces fiscal 2019 year-end results
    Oct 10,2019: Helix BioPharma announces Board changes
    Jun 11,2019: Helix BioPharma announces fiscal third quarter 2019 results
    May 30,2019: Helix BioPharma initiates OTCQB application and hires U.S. investor relations firm
    Mar 18,2019: Helix BioPharma announces fiscal second quarter 2019 results

    Key benefits of buying this profile include:

    You get detailed information about the company and its operations to identify potential customers and suppliers.
    The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

    Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
    The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

    Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
    Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

    Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
    Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

    Gain key insights into the company for academic or business research.
    Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

    Note: Some sections may be missing if data is unavailable for the company


    Section 1 - About the Company
    Helix BioPharma Corp - Key Facts
    Helix BioPharma Corp - Key Employees
    Helix BioPharma Corp - Key Employee Biographies
    Helix BioPharma Corp - Major Products and Services
    Helix BioPharma Corp - History
    Helix BioPharma Corp - Company Statement
    Helix BioPharma Corp - Locations And Subsidiaries
    Head Office
    Other Locations & Subsidiaries
    Section 2 – Company Analysis
    Company Overview
    Helix BioPharma Corp - Business Description
    Helix BioPharma Corp - Corporate Strategy
    Helix BioPharma Corp - SWOT Analysis
    SWOT Analysis - Overview
    Helix BioPharma Corp - Strengths
    Helix BioPharma Corp - Weaknesses
    Helix BioPharma Corp - Opportunities
    Helix BioPharma Corp - Threats
    Helix BioPharma Corp - Key Competitors
    Section 3 – Company Financial Ratios
    Financial Ratios - Capital Market Ratios
    Financial Ratios - Annual Ratios
    Performance Chart
    Financial Performance
    Financial Ratios - Interim Ratios
    Financial Ratios - Ratio Charts
    Section 4 – Company’s Lifesciences Financial Deals and Alliances
    Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
    Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
    Helix BioPharma Corp, Recent Deals Summary
    Section 5 – Company’s Recent Developments
    Oct 24, 2019: Helix BioPharma announces fiscal 2019 year-end results
    Oct 10, 2019: Helix BioPharma announces Board changes
    Jun 11, 2019: Helix BioPharma announces fiscal third quarter 2019 results
    May 30, 2019: Helix BioPharma initiates OTCQB application and hires U.S. investor relations firm
    Mar 18, 2019: Helix BioPharma announces fiscal second quarter 2019 results
    Feb 11, 2019: Helix BioPharma announces strategic corporate update
    Feb 08, 2019: Helix BioPharma Board changes
    Dec 14, 2018: Helix Biopharma announces fiscal first quarter 2019 results
    Oct 26, 2018: Helix BioPharma announces fiscal 2018 year-end results
    Sep 12, 2018: Helix BioPharma collaborator ProMab Biotechnologies publishes paper on multiple myeloma CAR-T
    Section 6 – Appendix
    Methodology
    Ratio Definitions
    About GlobalData
    Contact Us
    Disclaimer
    List of Tables
    Helix BioPharma Corp, Key Facts
    Helix BioPharma Corp, Key Employees
    Helix BioPharma Corp, Key Employee Biographies
    Helix BioPharma Corp, Major Products and Services
    Helix BioPharma Corp, History
    Helix BioPharma Corp, Subsidiaries
    Helix BioPharma Corp, Key Competitors
    Helix BioPharma Corp, Ratios based on current share price
    Helix BioPharma Corp, Annual Ratios
    Helix BioPharma Corp, Interim Ratios
    Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
    Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
    Helix BioPharma Corp, Recent Deals Summary
    Currency Codes
    Capital Market Ratios
    Equity Ratios
    Profitability Ratios
    Cost Ratios
    Liquidity Ratios
    Leverage Ratios
    Efficiency Ratios
    List of Figures
    Helix BioPharma Corp, Performance Chart (2015 - 2019)
    Helix BioPharma Corp, Ratio Charts
    Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
    Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook